MACROGENICS INC
For the period ended Dec 31, 2023. Filed Mar 7, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 7, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
10b5-1 Trading Plans
During the three months ended December 31, 2023 the following Section 16 officer and directors adopted, modified orterminated a “Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K of the Exchange Act):
James Karrels, Senior Vice President and Chief Financial Officer, adopted a new trading plan on December 8, 2023 (with the first trade possible under the new plan no sooner than April 16, 2024). The trading plan will be effective until April 15, 2025 and covers the potential sale of up to 490,000 shares of common stock. (1)
Jeffrey Peters, Senior Vice President and General Counsel, adopted a new trading plan on December 8, 2023 (with the first trade possible under the new plan no sooner than April 4, 2024). The trading plan will be effective until March 20, 2025 and covers the potential sale of up to 370,842 shares of common stock. (2)
(1) Mr. Karrels’ plan as adopted December 8, 2023 covered the potential sale of additional shares that were since sold under a prior existing plan. The total provided here reflects the maximum remaining shares available to sell under the December 8, 2023 plan as of March 5, 2024.
(2) Mr. Peters’ plan as adopted December 8, 2023 covered the potential sale of additional shares that were since sold under a prior existing plan. The total provided here reflects the maximum remaining shares available to sell under the December 8, 2023 plan as of March 5, 2024.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.